24 August 2018
EMA/576422/2018
Inspections, Human Medicines Pharmacovigilance & Committees Division

Scientific recommendation on classification of advanced therapy medicinal products

Article 17 – Regulation (EC) No 1394/2007

Disclaimer: This document is a summary for public release of a scientific recommendation on classification of advanced therapy medicinal products. The original text adopted by the Committee for Advanced Therapies (CAT) has been redacted to delete commercially confidential information.

The present scientific recommendation refers exclusively to the case as presented to the European Medicines Agency (EMA) without prejudice to future evaluations by the Agency.

It is stressed that the scientific recommendation on advanced therapy classification does not amount to any endorsement of the plausibility of the product, including the mode of action or therapeutic indication(s) claimed by the applicant.

Brief description (or name when available) of the active substance(s)

Autologous concentrated bone marrow.

Brief description of the finished product

Autologous concentrated bone marrow.

Proposed indication

Treatment of critical limb ischemia without surgical option.

EMA / CAT conclusion

The procedure was finalised on 1 July 2016 for the following recommendation.

On the basis that the product:

- contains engineered cells that are intended to be used for a different essential function;
- is administered to humans with a view of regenerating a human tissue,

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5555
Send a question via our website www.ema.europa.eu/contact

the EMA/CAT considers that the product falls within the definition of a tissue engineered product, as provided in Article 2(1) of Regulation (EC) 1394/2007.